The NephCure Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2013
NCT01835639
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

mycophenolate (CellCept) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Other Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nephrosis (Phase 3)

Nephrotic Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3